Chinmay Jani, Chief Fellow of Hematology and Oncology at Sylvester Comprehensive Cancer Center at the University of Miami, shared a post on X:
“Durvalumab is reshaping the treatment landscape in SCLC.
Managed Healthcare article highlighting our recent JCO GO analysis showcases how meaningful survival gains with immunotherapy are driving changes in standard of care – while also raising important questions around value and affordability.”
More posts featuring Chinmay Jani.